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Abstract
Background: Glucocorticoids have been shown to be effective in the treatment of autoimmune
diseases of the CNS such as multiple sclerosis and its animal model, experimental autoimmune
encephalomyelitis (EAE). However, the mechanisms and the site of glucocorticoids' actions are still
not completely defined. The aim of this study was to investigate the in vivo effect of the synthetic
glucocorticoid methylprednisolone (MP) on the expression and production of proinflammatory
cytokines interferon (IFN)-γ and interleukin (IL)-17 by cells infiltrating CNS tissue.
Methods: Experimental autoimmune encephalomyelitis was induced in Dark Agouti (DA) rats by
immunization with rat spinal cord homogenate mixed with adjuvants. Commencing on the day
when the first EAE signs appeared, DA rats were injected daily for 3 days with MP and/or RU486,
an antagonist of glucocorticoid receptor. Cytokine production and gene expression in CNS-
infiltrating cells and lymph node cells were measured using ELISA and real time PCR, respectively.
Results: Treatment of rats with MP ameliorated EAE, and the animals recovered without relapses.
Further, MP inhibited IFN-γ and IL-17 expression and production in cells isolated from the CNS of
DA rats with EAE after the last injection of MP. The observed effect of MP in vivo treatment was
not mediated through depletion of CD4+ T cells among CNS infiltrating cells, or through induction
of their apoptosis within the CNS. Finally, the glucocorticoid receptor-antagonist RU486 prevented
the inhibitory effect of MP on IFN-γ and IL-17 production both in vitro and in vivo, thus indicating
that the observed effects of MP were mediated through glucocorticoid receptor-dependent
mechanisms.
Conclusion: Taken together, these results demonstrate that amelioration of EAE by exogenous
glucocorticoids might be, at least partly, ascribed to the limitation of effector cell functions in the
target tissue.
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Background
Multiple sclerosis (MS) is a chronic, inflammatory, demy-
elinating disease of the CNS with a putative autoimmune
pathogenesis [1]. Its widely used model is experimental
autoimmune encephalomyelitis (EAE), an organ-specific
autoimmune inflammatory disease induced in suscepti-
ble animals, shows significant similarities to MS in both
clinical and pathological aspects [2]. Both diseases are
assumed to be mediated by myelin-specific CD4+ T lym-
phocytes, and more specifically by Th1 and Th17 cells.
Although the relative contribution of each Th subset has
not been clearly defined, there are reports of an encepha-
litogenic potential of both Th1 and Th17 cells and their
signature cytokines, IFN-γ and IL-17, respectively [3,4].
Glucocorticoids (GC) are used to treat a wide range of
inflammatory, allergic and autoimmune diseases, and
they have been shown effective in the treatment of acute
relapses in MS [5], as well as of EAE [6]. Multiple mecha-
nisms are proposed to explain glucocorticoid therapeutic
efficacy in autoimmune damage to the CNS [7], since GC
down-regulate both innate and adaptive immune
responses. Namely, GC have been shown to inhibit lym-
phocyte proliferation and lymphocyte expression and
production of various pro-inflammatory cytokines and
mediators (e.g. IL-1β, IL-6, TNF-α), while enhancing the
expression of anti-inflammatory cytokines (e.g. IL-10,
TGF-β), T-cell apoptosis and redistribution, a shift in the
population of Th cells from Th1 to Th2 [8,9] and the pro-
portion of regulatory cells [10]. We have recently demon-
strated that methylprednisolone (MP), a synthetic
glucocorticoid, inhibits the in vitro expression and pro-
duction of IL-17 in myelin basic protein (MBP)-stimu-
lated draining lymph node cells (DLNC) and cells
infiltrating CNS of EAE rats [11].
Although abundant data about diverse glucocorticoid
effects have been accumulated, the mechanisms underly-
ing the beneficial effects of glucocorticoids and the major
site of their action relevant to therapeutic efficiency in T
cell-mediated CNS autoimmune diseases, such as MS and
EAE, are not fully understood. Recent evidence from EAE
induced in C57BL/6 mice suggests that the major targets
of GC action are peripheral rather than CNS-residing T
lymphocytes [12]. On the contrary, plentiful data con-
vincingly demonstrate that GC directly influences cells
within the target tissue [reviewed in [13]]. Therefore, in
this study we investigated the effect of the synthetic gluco-
corticoid methylprednisolone (MP), on the expression
and production of IFN-γ and IL-17 by T lymphocytes infil-
trating CNS tissue in a rat model of EAE. We found that
MP applied in vivo inhibited IFN-γ and IL-17 generation
by the cells infiltrating the CNS. This inhibition correlated
with a reduction of clinical signs of EAE in MP-treated ani-
mals, thus suggesting that the inhibition of IFN-γ and IL-
17 within the CNS contributes to the beneficial effects of
glucocorticoids in neuroinflammatory diseases.
Methods
Experimental animals and EAE induction
Inbred Dark Agouti (DA) rats were obtained from the ani-
mal breeding facility of the Institute for Biological
Research "Siniša Stanković" (Belgrade). Age- and gender-
matched animals, between 12 and 16 weeks of age, were
used in the experiments. They were housed under conven-
tional conditions with laboratory chow and water ad libi-
tum. DA rats were immunized by intradermal injection in
the hind footpad of 100 μl of emulsion made by a mixture
of equal volumes of rat spinal cord homogenate (SCH) in
phosphate-buffered saline (PBS) (50% w/v) and complete
Freund's adjuvant (CFA; Difco Laboratories, Detroit, MI),
as described previously [14]. Animals were monitored
daily for clinical signs of EAE, and scored according to the
following scale: 0, no clinical signs; 1, flaccid tail; 2, hind
limb paresis; 3, hind limb paralysis; 4, moribund state or
death.
Treatment with MP and RU486
Beginning on the day when the first neurological signs
appeared (designated as day 1) DA rats were injected daily
for 3 days with methylprednisolone (MP, 50 mg/kg body
weight, Hemofarm, Vršac, Serbia) or with MP+RU486 (25
mg/kg, Sigma-Aldrich, St. Louis, MO) or with PBS. Three
hours after the last injection the animals were sacrificed
and extensively perfused with cold PBS through the left
ventricle. All animal experiments were carried out on the
basis of respective protocols approved by the University of
Belgrade School of Medicine Animal Ethics Committee
(no 1320/1-3) and in accordance with the U.K. Animals
(Scientific Procedures) Act, 1986 and associated guide-
lines, the European Communities Council Directive of 24
November 1986 (86/609/EEC).
Isolation of lymph node cells, mononuclear cells from 
spinal cords and splenocytes
Draining (popliteal) lymph nodes (DLN) and spleens
(SP) were isolated from immunized rats and cervical
lymph nodes (CLN) were obtained from healthy animals.
The lymph nodes and spleens were passed through a steel
mesh in RPMI-1640 medium (Sigma-Aldrich, St Louis,
MO), and the obtained suspensions of cells (DLNC,
CLNC and SPC) were filtered through a nylon mesh,
washed and resuspended in RPMI with 5% fetal calf
serum (FCS) (PAA Laboratories, Pasching, Austria).
Mononuclear cells were isolated from the spinal cords of
individual immunized rats. Spinal cords were dissociated
through a wire mesh and centrifuged at 700 g for 2 min.
The pellets were then resuspended in 40% Percoll (Sigma-
Aldrich) and centrifuged on a discontinuous 40%:70%
Percoll gradient at 850 g for 55 min. The spinal cordJournal of Neuroinflammation 2009, 6:37 http://www.jneuroinflammation.com/content/6/1/37
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mononuclear cells (SCC) were collected from the 40%/
70% interface, two times washed (900 g for 5 min) in
RPMI supplemented with 5% FCS, and resuspended in
RPMI 5% FCS. SCC, DLNC and CLNC were grown at 5%
CO2 and 37°C in RPMI-1640 supplemented with antibi-
otics. After the isolation all the cells were counted in 0,2%
trypan blue solution using a hemocytometer. Peripheral
blood (PB) was isolated from the hearts of immunized
rats, mixed with Turk solution (10 μl of blood in 90 μl of
Turk solution) and the number of cells (PBC) was
counted using a hemocytometer.
Reverse transcription - real time polymerase chain 
reaction
In order to determine cytokine gene expression, real time
PCR was performed. Total RNA was isolated from the cells
immediately after isolation from spinal cords using mi-
Total RNA Isolation Kit (Metabion, Martinsried, Ger-
many), and reverse-transcribed using random hexamer
primers and MMLV (Moloney Murine Leukemia Virus)
reverse transcriptase, according to manufacturer's instruc-
tions (Fermentas, Vilnius, Lithuania). Prepared cDNAs
were amplified using Power SYBR® Green PCR Master Mix
(Applied Biosystems, Foster City, CA), according to the
recommendations of the manufacturer, in a total volume
of 20 μl in an ABI PRISM 7000 Sequence Detection Sys-
tem (Applied Biosystems). Thermocycler conditions com-
prised an initial step at 50°C for 5 minutes, followed by a
step at 95°C for 10 minutes and a subsequent 2-step PCR
program at 95°C for 15 seconds and 60°C for 60 seconds
for 40 cycles. The PCR primers (Metabion) were as fol-
lows: IFN-γ forward primer 5'-TGG CAT AGA TGT GGA
AGA AAA GAG-3'; IFN-γ- reverse primer 5'-TGC AGG ATT
TTC ATG TCA CCA T-3'; IL-17 forward primer 5'-ATC
AGG ACG CGC AAA CAT G-3'; IL-17 reverse primer 5'-
TGA TCG CTG CTG CCT TCA C-3'; IL-23 forward primer
5'-TCC ACC AAA CTC CCC AGA CA-3'; IL-23R reverse
primer 5'-CTG TGC ATG CTC TTT GGT TGA T-3'; RorG
forward primer 5'-GAC AGG GCC CCA CAG AGA-3';
RorG reverse primer 5'-TTT GTG AGG TGT GGG TCT TCT
TT-3'; T-Bet forward primer 5'-CCA ACA ATG TGA CCC
AGA TGA T-3'; T-bet reverse primer 5'-CTG GCT CAC CGT
CAT TCA-3'; β-actin forward primer 5'-GCT TCT TTG CAG
CTC CTT CGT-3'; β- actin reverse primer 5'-CCA GCG
CAG CGA TAT CG-3'. Accumulation of PCR products was
detected in real time and the results were analyzed with
7500 System Software (AB) and presented as 2-dCt, where
dCt was difference between Ct values of specific gene and
endogenous control (β-actin).
Cell-surface and intracellular staining and flow cytometric 
analysis
Anti-CD4-PE, anti-CD62L-biotin, OX40-biotin (all from
BD Biosciences, San Jose, CA) anti-CD11b-FITC, anti-
CD25-FITC (both from AbD Serotec, Oxford, UK) were
used for phenotype analysis of CNS-infiltrating cells.
Biotin-coupled antibodies were used in conjuction with
SAv-FITC Conjugate (BD Biosciences). Annexin V coupled
with FITC (Biotium Inc, Hayward, CA) was used for detec-
tion of apoptotic cells. Simultaneous detection of IFN-γ-
and IL-17-producing cells was performed using intracellu-
lar staining after a short stimulation (4 h) with phorbol
myristate acetate (PMA) (100 ng/ml) and ionomycin (400
ng/ml) in the presence of Brefeldin A (5 μM) (all from
Sigma-Aldrich). First, cells were stained for CD4 by incu-
bation with anti-CD4-PE antibody for 30 minutes, at
+4°C. Subsequently, the cells were fixed with 4% parafor-
maldehyde (PFA) for 20 min at room temperature (RT).
Cells were then stained with PE or FITC conjugated anti
mouse-IL-17 and corresponding isotype control (BD Bio-
sciences) and biotin conjugated anti-rat IFN-γ and corre-
sponding isotype control (Biosource, Carlsbad, CA),
followed by coupling with SAv-PerCP Conjugate (BD Bio-
sciences). All the incubations were performed in permea-
bilization buffer (PBS, FCS 2%, BSA 0.1%, Triton X-100
0.1%). The stained cells were acquired by a FACSCalibur
cytometer (BD Biosciences) and analyzed using CellQuest
Software (BD Biosciences).
ELISA
For determination of cytokine production, SCC were
seeded in 96-well plates (5 × 105/200 μl) and DLNC were
seeded in 24-well plates (2.5 × 106/1 ml) for 72 hours.
SCC were grown in medium alone, and DLNC and CLNC
in medium with concanavalin A (ConA, Sigma-Aldrich, 1
μg/ml). CLNC were cultivated in the presence of MP (10
ng/ml) with or without RU486 (5 ng/ml) for 24 hours.
Subsequently, cell culture supernatants were collected and
cells pelleted by centrifugation (5000 g, 3 min). Cell-free
supernatants were frozen until they were analyzed on the
basis of the protocol recommended by manufacturers of
the ELISA kits (OptEIA Mouse IL-17 Set, BD Biosciences;
Rat IFN-γ Set, R&D systems, Minneapolis, MI).
Statistical analysis
The results are presented as mean ± SD of data obtained
from at least three separate experiments with similar data.
Student's t test was performed for statistical analysis. A p
value of less than 0.05 was considered statistically signifi-
cant.
Results
MP ameliorates EAE in DA rats and reduces infiltration of 
encephalitogenic cells into the CNS
Rats were immunized with SCH-CFA and treated with MP
(50 mg/kg) for three consecutive days following the
appearance of initial clinical signs of EAE, to mimic ster-
oid pulse therapy in MS. Control rats, treated with vehicle
(PBS), were paired to MP-treated rats both according to
the severity of initial clinical signs and to the time of theJournal of Neuroinflammation 2009, 6:37 http://www.jneuroinflammation.com/content/6/1/37
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initial signs occurrence. In the group of control rats EAE
progressed more rapidly than in MP-treated rats (Fig. 1A).
Further, some rats from both MP-treated and control
groups were sacrificed and cells infiltrating spinal cord
(SCC) isolated for further analysis. Splenocytes (SPC),
peripheral blood cells (PBC) and draining lymph node
cells (DLNC) were also isolated from these rats. The
number of cells isolated from all of the tissues of the two
groups of rats sacrificed after 3-days of treatment differed
significantly, with lower numbers detected in MP-treated
rats (Fig 1B). The remaining rats were left for observation
after cessation of MP treatment, and it appeared that MP-
treated rats exhibited significantly milder disease com-
pared to controls (Fig 1A). No relapses were observed in
either group.
MP inhibits IFN-  and IL-17 expression and production in 
cells infiltrating CNS of EAE DA rats
In order to explore the potential of MP to influence IFN-γ
and IL-17 expression and production in cells infiltrating
CNS, mononuclear cells isolated from spinal cord (SCC)
were subjected to analyses of direct ex vivo RNA expression
and production, as well as PMA+ionomycin-stimulated
intracellular expression of IFN-γ and IL-17. MP applied in
vivo had a clear-cut inhibitory effect on IFN-γ and IL-17
gene expression in SCC (Fig 2A), as well as on spontane-
ous release of cytokines from these cells (Fig 2B). Also, MP
applied in vivo inhibited expression of the main Th1 and
Th17 transcription factors, Tbet and ROR-γT, respectively,
as well as of one of the markers of Th17 cells, IL-23R, in
SCC (2A). Interestingly, if SCC were stimulated with PMA
and ionomycin there were fewer cells expressing IFN-γ,
but not IL-17, among SCC isolated from MP-treated rats
in comparison to vehicle-treated rats (Fig 2C, D). SCC
capable of expressing both IFN-γ and IL-17 were also
observed and their percentage was moderately reduced
under the influence of MP (Fig 2C, D). Thus, these results
show that MP interferes with IFN-γ and IL-17 production
in cells infiltrating CNS during EAE. Similarly, treatment
of EAE rats with MP also affected spontaneous and ConA-
stimulated release of IFN-γ and IL-17 from DLNC (Fig 2E,
F).
MP does not influence the proportion of CD4+ cells among 
cells infiltrating CNS
In order to find out if the observed effect of MP on IFN-γ
and IL-17 expression is related to a change in proportion
of CD4+  lymphocytes as main producers of these
cytokines among cells infiltrating CNS, and to explore
whether apoptosis is induced in these cells under the
influence of MP, cells isolated from spinal cords of MP- or
PBS-treated rats were stained with labeled anti-CD4 and
anti-CD11b antibodies, or with labeled anti-CD4 anti-
body and AnnexinV, and subjected to cytofluorimetric
analysis. Among cells infiltrating CNS there were popula-
tions of CD4+ T cells (CD4+brightCD11b-), of macro-
phages/monocytes (CD4+dimCD11b+  or CD4-CD11b+)
and of other cell types (CD4-CD11b-) (Fig 3A). The per-
centage of CD4+ T cells did not differ between MP-treated
and control animals (Fig 3A). Moreover, the percentage of
CD62L+  (marker of naïve T cells), CD25+  (activation
marker of T cells) and OX40+ (marker of activated T cells)
cells was similar between MP-treated and control animals
(Fig 3B). In addition, the proportion of AnnexinV+ (apop-
totic) cells among CD4+ cells was determined, and no dif-
ference was found between the MP-treated and control
groups (Fig 3C). Thus, we could conclude that the
observed effect of MP in vivo treatment was not mediated
through modulation of the proportion of CD4+ T cells
among cells infiltrating the CNS. We could also conclude
that MP did not alter the proportions of naïve and effector
cells within the CD4+ T cell population. Importantly, the
difference in the effects of MP on IFN-γ and IL-17 in
PMA+ionomycin-stimulated SCC was also evident if anal-
yses of intracellular cytokine expression were restricted to
CD4+ cells (Fig 3D, E), thus suggesting that MP down-reg-
ulated IFN-γ, but not IL-17, in CNS-infiltrating Th popu-
lations stimulated with PMA and ionomycin.
RU486 prevents downregulatory effects of MP on IFN-  
and IL-17 production by CNS-infiltrating cells
Further, we explored if the inhibitory effect of MP on IFN-
γ and IL-17 production is dependent on glucocorticoid
receptor engagement. Thus, we used a well-recognized
glucocorticoid receptor antagonist RU486 [6]. First, we
applied this agent in vitro, where cervical lymph node cells
from healthy rats were stimulated with ConA in the pres-
ence or absence of MP and/or RU486. As a result, it was
clear that RU486 antagonized the inhibition imposed
upon ConA-stimulated CLNC by the influence of MP (Fig
4A, B). In order to investigate if the observed inhibition of
IFN-γ and IL-17 production by SCC after in vivo MP treat-
ment is mediated through glucocorticoid receptor-
dependent mechanisms, DA rats were immunized with
SCH-CFA and treated either with MP (50 mg/kg) or with
MP (50 mg/kg) and RU486 (25 mg/kg) for three consecu-
tive days following appearance of initial clinical signs of
EAE. Control rats, treated with vehicle (PBS), MP-treated
rats and MP+RU486-treated rats were paired both accord-
ing to the severity of initial clinical signs and to the time
of the initial signs occurrence. Importantly, RU486 antag-
onized the effect of MP on EAE clinical course (Fig 4C), as
well as its effect on IFN-γ and IL-17 production by SCC
(Fig 4D). Thus, these results imply that the inhibitory
effect of MP on IFN-γ and IL-17 production both in vitro
and in vivo is mediated through the glucocorticoid recep-
tor.
Discussion
This study demonstrates that MP given in vivo to DA rats
with first signs of EAE, by a regimen that leads to signifi-
cant amelioration of the disease, inhibits the expressionJournal of Neuroinflammation 2009, 6:37 http://www.jneuroinflammation.com/content/6/1/37
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MP treatment ameliorates EAE in DA rats and decreases infiltration of cells into the CNS Figure 1
MP treatment ameliorates EAE in DA rats and decreases infiltration of cells into the CNS. DA rats were immu-
nized with SCH-CFA. Commencing on the day when first neurological signs appeared (designated as day 1), DA rats were 
injected daily for 3 days with methylprednisolone (MP, 50 mg/kg body weight) or with phosphate-buffered saline (PBS). The 
rats were checked daily for clinical signs of EAE. For the determination of the clinical course of EAE, 19 animals per group (out 
of four independent experiments) were used. (A). Three hours after the last injection of MP some animals were sacrificed, and 
cells infiltrating spinal cord, splenocytes, peripheral blood cells, and draining lymph node cells were isolated and counted (B). *p 
< 0.05 represents statistically significant difference between MP and PBS group.Journal of Neuroinflammation 2009, 6:37 http://www.jneuroinflammation.com/content/6/1/37
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and production of IFN-γ and IL-17 by CNS-infiltrating
cells, thus suggesting that the beneficial effect of MP in
EAE is partly mediated through restraining immune
responses within the CNS. Limitation of production of
IFN-γ and IL-17 in the CNS is of importance for the bene-
ficial effects of MP, as abundant data confirm the patho-
genic role for IFN-γ and IL-17 in autoimmune diseases,
although their contribution to the disease process proba-
bly depend on the epitope-specificity of encephalitogenic
cells [3], localization of the disease process [4] and condi-
tions present during initial exposure to antigen, including
the quality/quantity of Toll-like receptor stimulation and
type of antigen-presenting cells [15]. In the EAE model in
DA rats used in this study, it appears that both Th1 and
Th17 cells with their marker cytokines play a role in the
disease process [4].
The effects of glucocorticoids on immune cells can be
mediated through glucocorticoid receptor-dependent and
independent actions [16]. In fact, glucocorticoids bring
about the majority of their effects upon interaction with a
cytoplasmic glucocorticoid receptor (GR) which, subse-
quent to ligand binding, dissociates from chaperone pro-
teins, forms dimers, and translocates into the nucleus
where it modulates gene expression either by direct bind-
ing to its cognate response elements or via interaction
with other transcription factors [17]. Recently, a new con-
cept of non-genomic actions of glucocorticoids emerged
which assumes that activated glucocorticoid receptor may
produce effects without an action on gene transcription
[reviewed in [18]]. Moreover, some effects of glucocorti-
coids may also be exerted without involvement of a GR;
they are mediated by membrane-bound GRs, or as a result
of direct, nonspecific interactions with cell membranes
[18]. Therefore, we analyzed the effects of RU486, an
antagonist of glucocorticoid receptor [6], in our experi-
mental system and showed that this drug counteracted
MP in its effect on EAE course, as well as in its in vitro and
in vivo effects on IFN-γ and IL-17 generation. These results
exclude the possibility that the effect of MP might result
MP inhibits IFN-γ, but not IL-17 production, in cells infiltrating the CNS of DA rats with EAE Figure 2
MP inhibits IFN-γ, but not IL-17 production, in cells infiltrating the CNS of DA rats with EAE. SCC and DLNC 
were isolated from DA rats immunized with SCH-CFA and injected with MP or PBS, as described in Methods. RNA was iso-
lated from SCC and RT-PCR was performed (A), or SCC were grown in medium and ELISA was performed from cell-free 
supernatants obtained after 72 hours of cultivation (B). Alternatively, SCC from PBS-treated (C) and MP-treated (D) rats were 
stained for IFN-γ and IL-17. Results of intracellular staining (C, D) are representative of three independent experiments. The 
numbers in the plots are means ± SD of the proportions of cells present in the corresponding quadrant obtained in four inde-
pendent experiments. DLNC were cultivated without (E) or with (F) 1 μg/ml of ConA for 72 hours and cell-culture superna-
tants were analyzed by ELISA. *p < 0.05 represents a statistically significant difference between the MP and PBS groups.Journal of Neuroinflammation 2009, 6:37 http://www.jneuroinflammation.com/content/6/1/37
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from its binding to membrane receptors or subcellular
structures other than the glucocorticoid receptor. Moreo-
ver, since RU486 prevents the translocation of the glu-
cocrticoid-GR complex to the nucleus [19], these results
confirm that the observed inhibition of IFN-γ and IL-17
represents a genomic effect of MP.
In this study MP treatment commencing with the first
clinical signs of actively induced EAE was applied to
mimic application of the drug in acute relapses of MS in
humans. In accordance with previously published results
showing beneficial effects of GC treatment on EAE [8], MP
treatment led to a significant amelioration of clinical signs
MP does not affect CD4+ cell proportion or apoptosis rate among CNS-infiltrating cells Figure 3
MP does not affect CD4+ cell proportion or apoptosis rate among CNS-infiltrating cells. SCC were isolated from 
DA rats immunized with SCH-CFA, and injected with MP or with PBS, as described in Methods. SCC were stained with anti-
CD4 and anti-CD11b specific antibodies (A), with anti-CD4 and anti-CD62L or anti-OX40 or anti-CD25 specific antibodies 
(B), or with anti-CD4 specific antibody and Annexin V (C). Alternatively, SCC from PBS-treated (D) and MP-treated (E) rats 
were stained with anti-CD4 antibody and intracellular staining for IFN-γ and IL-17 was performed. The results presented in B-
E are gated to CD4+ cells. Results of intracellular staining (D, E) are representative of three independent experiments. *p < 
0.05 represents a statistically significant difference between the MP and PBS groups.Journal of Neuroinflammation 2009, 6:37 http://www.jneuroinflammation.com/content/6/1/37
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of EAE in DA rats. The inhibitory effect of MP in this
model of EAE was maintained throughout the follow-up
evaluation period, 8 days after methylprednisolone with-
drawal, with no relapse of disease. This observation is in
agreement with a previously published report in which
the authors applied a similar concentration of dexameth-
asone by the same application regime in active EAE in
C57BL/6 mice [12]. However, if glucocorticoids are
applied in lower concentration [20], or they are applied
per os [10] or they are applied for a longer time [21] and
then withdrawn, worsening of clinical features, reappear-
ance of the CNS inflammatory infiltrate and lymphocyte
reactivity to the encephalitogen are reported. Thus, it
seems that the mode of glucocorticoid application is of
utmost importance for their effect on EAE.
Multiple mechanisms have been postulated to be respon-
sible for the beneficial effect of glucocorticoids on CNS
autoimmunity [7], while peripheral T lymphocytes have
been considered as the main therapeutic target [12]. How-
ever, an extensive literature demonstrates that glucocorti-
coids are effective in reducing CNS inflammation by
direct action on cells within the CNS [reviewed in [13]].
Here, we show that the number of cells isolated from the
spinal cord of MP-treated animals was significantly lower
than the number of cells isolated from control rats in EAE.
This could be a consequence of the inhibition of encepha-
litogenic cell infiltration into the CNS that has been previ-
ously reported following treatment of EAE with
glucocorticoids [10]. The limitation of the infiltration
might be explained by increased apoptosis and weaker
activation of encephalitogenic cells in lymphoid organs,
by decrease in expression of adhesion molecules on leu-
kocytes and endothelial cells of the blood brain barrier
(BBB), as well as by increased integrity of BBB [22,23,8].
On the other hand, fewer infiltrating cells within the CNS
of MP-treated rats might also be a consequence of
increased rate of apoptosis of these cells in the CNS, as
previously suggested [24]. However, we could not detect
increased cell death rate under the influence of MP in EAE
rats, which is in accordance with a recent investigation
performed in mice [12]. We have to emphasize that there
is a possibility that a number of apoptotic cells was lost in
the procedure of cell isolation, and that in vivo numbers
of apoptotic cells in MP-treated animals might be higher
within the CNS. However, this would still mean that
among cells isolated from the CNS there is no difference
in apoptosis regardless of the treatment with MP. The
absence of increased apoptosis within the CNS of MP-
treated rats might be explained by the dual death-related
influence of glucocorticoids on T cells, as glucocorticoids
induce apoptotic death of T cells but also protect them
against CD95-mediated apoptosis, including activation-
induced cell death, probably due to suppression of FasL
expression [25] and/or an increase in Bcl-2 expression
[26]. Still, the number of immune cells was down-regu-
lated across various peripheral lymphoid tissues and
blood under the influence of MP, and it seems reasonable
to assume that apoptosis of these cells is at least partly
responsible for the effect of MP. Apoptosis in the periph-
ery could also be one of the major reasons for the
decreased number of cells infiltrating the CNS.
RU486 prevents inhibition of IFN-γ and IL-17 by MP Figure 4
RU486 prevents inhibition of IFN-γ and IL-17 by MP. (A) DA rats were immunized with SCH-CFA. Commencing on the 
day when first neurological signs appeared (designated as day 1) DA rats were injected daily for 3 days with methylpred-
nisolone (MP, 50 mg/kg body weight) and/or RU486 (25 mg/kg body weight) or with phosphate-buffered saline (PBS). The rats 
were checked daily for clinical signs of EAE. For the determination of the clinical course of EAE, 15 animals per group (out of 
three independent experiments) were used. (B, C) CLNC from healthy animals were stimulated with ConA (1 μg/ml) in the 
presence or absence of MP (10 ng/ml) and/or RU486 (5 ng/ml) for 24 hours. Cell-free supernatants of the cultures were ana-
lyzed with ELISA for IFN-γ (B) and IL-17 (C) concentrations. (D) SCC were isolated from DA rats immunized with SCH-CFA 
and injected with PBS, or with MP, or with MP+RU486, as described in Methods. Cell-free supernatants of cultures of SCC 
grown in medium for 72 hours were analyzed with ELISA for IFN-γ and IL-17 concentrations. *p < 0.05 represents a statisti-
cally significant difference between the MP and PBS treatment groups, and 'p < 0.05 represents a statistically significant differ-
ence between the MP and MP+RU486 treatment groups.Journal of Neuroinflammation 2009, 6:37 http://www.jneuroinflammation.com/content/6/1/37
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In addition to the limitation of immune cells infiltration
in the CNS, the restriction of pro-inflammatory potential
of infiltrated cells could also be of importance for the ben-
eficial effects of MP in EAE. Indeed, if equivalent numbers
of spinal cord-infiltrating cells from MP-treated and con-
trol rats are compared, a significant difference in IFN-γ
and IL-17 expression and production is observed. Thus,
besides diminishing the number of infiltrating cells
within the CNS, MP also restrains their pro-inflammatory
i.e. autoimmune potential. As the major producers of
these cytokines in the CNS of EAE rats are CD4+ cells, the
downregulation of cytokine production and expression in
SCC might be a consequence of a reduced CD4+ cell pro-
portion among CNS-infiltrating cells. However, again in
agreement with the findings of Wüst and colleagues [12],
we do not find a difference in the percentage of CD4+ cells
among CNS-infiltrating cells. Moreover, there is no differ-
ence in the proportion of naive and activated cells within
the population of CD4+ cells, thus excluding the possibil-
ity that MP affects IFN-γ and IL-17 production through
specific reduction of activated CD4+ cells among CNS
infiltrating cells.
While a large body of evidence shows that glucocorticoids
inhibit Th1 and IFN-γ in EAE [reviewed in [27]], the influ-
ence of glucocorticoids on Th17 and their signature
cytokine IL-17 has not been investigated in detail so far.
We have recently shown that MP inhibits IL-17 in vitro,
but to a lesser extent than it influences IFN-γ [11], and to
that we add the similar observation from this study about
IL-17 inhibition in the CNS of MP-treated rats. The even-
tual importance of other cytokines, or other regions which
could also be affected, is not excluded.
Interestingly, when SCC were stimulated with PMA+iono-
mycin and intracellular detection of IFN-γ and IL-17 was
performed, the proportion of IFN-γ-producing, but not of
IL-17-producing cells, was reduced in cells isolated from
MP-treated rats in comparison to control rats. The propor-
tion of these cells that are capable of expressing both
cytokines, and that have recently been described in DA rat
EAE [14], was also not affected by MP treatment, thus sug-
gesting that these cells are more similar to Th17 than to
Th1, at least regarding sensitivity to glucocorticoid regula-
tion. This implies that although MP applied in vivo
restrains generation capacity of both cytokines within the
CNS, SCC released from the CNS environment and stim-
ulated with strong unspecific stimulus regain the potential
to produce IL-17, but not IFN-γ. Importantly, the same
observation was valid for SCC in general and for CD4+
cells i.e. Th1 and Th17 cells. Thus, it seems that after
PMA+ionomycin treatment, spinal cord-derived T cells
display an apparent shift from Th1 to Th17 cells Although
we do not yet have an explanation for these findings, it is
tempting to speculate that the influence of MP on Th1
might be direct, while the drug might affect Th17 cells and
their cytokines through its effect on CNS resident cells,
which have previously been shown to modulate IL-17
production at least in vitro [28,29]. Alternatively, there
might be a difference in the duration of the inhibitory
effect of MP on Th1 and Th17 cells, and stimulation with
PMA and ionomycin takes 4 hours, which is enough time
to express cytokines in lymphocytes. Also, there is a possi-
bility that PMA+ionomycin, as a strong artificial treat-
ment, may skew the result through stimulation of both
encephalitogenic and bystander cells. It remains for future
investigations to determine the mechanism underlying
the observed difference between ex vivo and post-activa-
tion IL-17 expression in SCC from MP-treated animals. It
would also be important to find out if this property of
Th17 cells might be of relevance for the pathology of CNS
neuroinflammation, especially regarding contribution of
endogenous glucocorticoids to pathology resolution.
Conclusions
Our data reveal a significant influence of MP on the
expression and production of IFN-γ and IL-17 within the
CNS in EAE. Thus, the beneficial effects of glucocorticoids
in neuroinflammation are at least partly mediated
through their ability to limit production of the inflamma-
tion-promoting cytokines IFN-γ and IL-17 in target tissue.
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